COMIRNATY DIN 02552078
Status: Approved
Holder: BIONTECH MANUFACTURING GMBH
Health Canada record
| Active ingredient(s) | *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER 3 MCG |
|---|---|
| Dosage form | Suspension |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BN01 COVID-19, RNA-BASED VACCINE |
| Original market date | |
| Current status date | 24-Sep-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
BioNTech Manufacturing Marburg GmbH — licence , not currently licensed, last inspection rating C (2024-09-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02541823 | COMIRNATY | BIONTECH MANUFACTURING GMBH | Suspension | *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER 30 MCG | Marketed |
| 02541858 | COMIRNATY | BIONTECH MANUFACTURING GMBH | Suspension | *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER 10 MCG | Marketed |
| 02552035 | COMIRNATY | BIONTECH MANUFACTURING GMBH | Suspension | *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER 30 MCG | Marketed |